Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
OPERATING ACTIVITIES:
Consolidated net loss	$ (2,226)	$ 997
Adjustments to reconcile consolidated net (loss) income to net cash provided by (used in) operating activities:
Bad debt expense	82	13
Depreciation and amortization	1,795	1,155
Stock-based compensation expense	687	498
Amortization of debt issuance cost	7	4
Tax payments related to shares cancelled for vested restricted stock awards	(12)	(19)
Deferred income taxes	(918)	126
Changes in operating assets and liabilities:
Trade accounts receivable	5,438	229
Inventories	850	(3,980)
Other current assets	4,570	(1,006)
Right of use assets	300	78
Other long-term assets	(18)	224
Accounts payable	(2,950)	1,464
Accrued expenses	(4,307)	1,261
Income taxes payable	(760)	0
Net cash provided by operating activities	2,574	596
INVESTING ACTIVITIES:
Capital expenditures	(2,311)	(430)
Purchase of Microlab, net of cash acquired ($33)	0	(24,442)
Net cash used in investing activities	(2,311)	(24,872)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options	86	149
Debt issuance cost	0	(32)
Revolving credit facility	1,000	(0)
Term Loan payments	(1,818)	(808)
Term Loan	0	17,000
Net cash (used in) provided by financing activities	(732)	16,309
Net decrease in cash and cash equivalents	(469)	(7,967)
Cash and cash equivalents, beginning of period	4,532	13,053
Cash and cash equivalents, end of period	4,063	5,086
Supplemental cash flow information – income taxes paid	$ 19	$ 223